Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate. The disease is life threatening however, the severity of the disease varies.
The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.
The global bronchopulmonary dysplasia treatment market can be segmented based on drug type, therapy, end-user, and region. In terms of drug type, the market can be divided into bronchodilators, corticosteroids, diuretics, immunomodulators, and others. Based on therapy, the global bronchopulmonary dysplasia treatment market can be categorized into oxygen therapy, surfactant replacement therapy, mechanical ventilation, and others. The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as effectiveness of drugs and more commonly used therapy. Based on end-user, the global bronchopulmonary dysplasia treatment market can be classified into hospitals, nursing homes, critical care units, and others.
Geographically, the global bronchopulmonary dysplasia treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the global market, accounting for the largest share. High prevalence of the disease in the region and rise in premature birth rate are factors fueling the growth of the bronchopulmonary dysplasia treatment market in the region. Furthermore, advanced technology, rise in awareness among people about the treatment of the disease, and high health care expenditure augment the market in North America. Europe is also anticipated to hold a significant share of the global market. Asia Pacific is anticipated to register a faster growth rate during the forecast period. Asia Pacific is the most lucrative market due to a large patient pool, government programs and initiatives, rise in awareness toward treatment of the disease, and increase in health care expenditure.
Major players have adopted strategies such as robust R&D, mergers and acquisitions, cost effective and efficient drugs, and collaborative partnerships to capture leadership position in the global bronchopulmonary dysplasia treatment market. Key players operating in the market are Airway Therapeutics, LLC, Therabron Therapeutics, Syntrix Biosystems, Inc., CHIESI Farmaceutici S.p.A., among others.